Lyell Immunopharma Inc., a clinical-stage company focused on advancing next-generation CAR T-cell therapies for cancer treatment, announced a securities purchase agreement for a private placement with institutional and accredited investors, potentially raising up to $100 million. The initial closing is expected to yield approximately $50 million from the sale of common stock at $13.32 per share. The funds will support pivotal-stage clinical trials of LYL314 and other corporate purposes, with expectations to sustain financial needs into mid-2027. This includes funding through significant milestones such as a clinical trial data update from LYL314, the initiation of a Phase 3 trial for relapsed or refractory large B-cell lymphoma, and a trial for a new CAR T-cell therapy targeting an undisclosed solid tumor. Investors are provided with resale registration rights for the common stock shares issued in this financing.